Compare Pfizer Inc (PFE) vs Rivian Automotive, Inc. (RIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Rivian Automotive, Inc. — how do they compare? Pfizer Inc trades at $28.28 (market cap $158.56B), while Rivian Automotive, Inc. trades at $13.96 (market cap $20.75B). The key difference: Pfizer Inc is far larger — about 7.6× Rivian Automotive, Inc.'s market cap, and Pfizer Inc pays a 6.18% dividend while Rivian Automotive, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Rivian Automotive, Inc. for 61 Days on average.
| PFE | RIVN | |
|---|---|---|
Market Cap | $158.56B | $20.75B |
Volume | 44,138,282 | 26,144,654 |
Sector | Health | Consumer Cyclical |
52-Week High | $29.02 | $22.45 |
52-Week Low | $23.67 | $12.50 |
Typical Hold Time | 158 Days | 61 Days |
Enterprise Value | $210.06B | $20.79B |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Rivian Automotive (RIVN) trades at $13.96, down 2.65% amid bearish technical signals despite strong Q3 2026 delivery results. The company reported record production of 19,751 vehicles and deliveries of 19,248, beating estimates but maintaining unchanged guidance. Fundamentally, RIVN shows improving revenue growth ($5.39B in 2025) but continues significant losses (-$3.65B net income) with negative margins. Analyst consensus remains cautiously optimistic with a $16.89 price target, though technical indicators show 18 sell signals versus 2 buy signals.
Rivian's investment case balances strong delivery growth and R2 SUV ramp-up against persistent cash burn and competitive EV market pressures. The stock offers upside to analyst targets but faces execution risks in achieving profitability. Key catalysts include R2 production scaling and autonomy technology rollout, while main risks involve cash flow sustainability and intense industry competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →
